Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Supreme Court and Biosimilars: What if it All Goes Away?

This article was originally published in RPM Report

Executive Summary

After the bruising health care reform debate in Congress, biopharmaceutical companies were comfortably on the periphery of the legal arguments playing out in the Supreme Court. But being peripheral has its disadvantages: if the Court sides with the challengers, it is possible that one of the “peripheral” provisions tossed aside will be the new biosimilars pathway. That would be a disaster for innovator companies.

You may also be interested in...

Betting and Winning: SCOTUS Decision Underscores High Stakes In Pharma’s Strategy

The Supreme Court decision was a decisive victory for the biopharma industry for a number of reasons. But the drama that unfolded in a razor-close decision will continue as new milestones—political and legislative—approach.

The Ascent of Abbott: Humira Marketer Battles With FDA Over Biosimilars

Abbott Labs wasn’t considered a serious biologics manufacturer when the biosimilars pathway was first being debated. But with the arthritis treatment Humira now the world’s best-selling pharmaceutical brand, the company has assumed a leadership position just as the biosimilar opportunity is emerging. And what better way to use that new role than by launching an offensive strike against FDA?

Reimbursement of Biosimilar and Biosimilar-similar ESAs

Affymax received FDA approval for the first new ESA in years. Now the company is trying to secure favorable reimbursement for its product, Omontys. The case raises the question of how CMS will treat biosimilar ESAs.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts